{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:10:07Z","timestamp":1781104207974,"version":"3.54.1"},"reference-count":37,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s310619","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T09:00:15Z","timestamp":1631264415000},"page":"789-800","source":"Crossref","is-referenced-by-count":2,"title":["Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Anshul","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Tosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Ambavane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-2369","authenticated-orcid":true,"given":"Andreas","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmina","family":"Hogea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-5585","authenticated-orcid":true,"given":"Yevgeniy","family":"Samyshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M","family":"Maiese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,9]]},"reference":[{"key":"ref1","unstructured":"National Institutes of Health. National Cancer Institute; Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Myeloma; 2020. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed October 07, 2020."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","volume":"2","author":"Verelst","year":"2018","journal-title":"Hemasphere"},{"key":"ref6","unstructured":"NCCN. NCCN guidelines. Multiple myeloma. v2.2021. 2020."},{"key":"ref7","unstructured":"GlaxoSmithKline. BLENREP (belantamab mafodotin-blmf) prescribing information. 2020."},{"key":"ref8","unstructured":"Karyopharm Therapeutics, Inc. XPOVIO (selinexor) prescribing information. 2019."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.HS9.0000560524.63281.bc","volume":"3","author":"Montes De Oca","year":"2019","journal-title":"HemaSphere"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. Epub 2021 Jul 27. doi: 10.1002\/cncr.33809","DOI":"10.1002\/cncr.33809"},{"key":"ref16","first-page":"204","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/CEOR.S251070","volume":"12","author":"Bassali","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref19","first-page":"272","volume":"25","author":"Runyan","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"AMCP Format Executive Committee. The AMCP format for formulary submissions: welcome to version 4.0. J Manag Care Spec Pharm. 2016;22(5):444\u2013446.","DOI":"10.18553\/jmcp.2016.16071"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Rakesh P, Suvannasankha A, Kapetanakis V, et al. DREAMM-2: assessing efficacy via indirect comparison of single-agent belantamab mafodotin versus selinexor plus dexamethasone combination in anti-CD38 exposed relapsed\/refractory multiple myeloma. Poster presented at the 25th European Hematology Association (EHA) Congress; 2020; Virtual Format.","DOI":"10.1200\/JCO.2020.38.15_suppl.e20527"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/10428194.2017.1361035","volume":"59","author":"MacEwan","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref25","unstructured":"GSK Data on File. GSK study 205678; NCT03525678."},{"key":"ref26","unstructured":"Nikolaou A, Maiese E, Samyshkin Y, et al. Estimating the number of US patients with multiple myeloma at 5 or more Lines of Treatment (LOT). International Society for Pharmacoeconomics and Outcomes Research; 16\u201319 November, 2020; Virtual. Available from: https:\/\/europe2020-ispor.ipostersessions.com\/Default.aspx?s=79-B4-D0-A2-C1-BB-30-AE-22-AA-D9-4D-BD-EF-49-8A&pdfprint=true&guestview=true. Accessed August 31, 2021."},{"key":"#cr-split#-ref27.1","unstructured":"US Census Bureau. Annual estimates of the resident population for selected age groups by sex for the United States, Counties, and Puerto Rico Commonwealth and Municipios: April 1, 2010 to July 1, 2018. 2018 population estimates"},{"key":"#cr-split#-ref27.2","unstructured":"2019. Available from: https:\/\/www2.census.gov\/programs-surveys\/popest\/tables\/2010-2018\/counties\/asrh\/PEPAGESEX.pdf. Accessed November 01, 2019."},{"key":"ref28","unstructured":"Institute for Clinical and Economic Review (ICER). Treatment options for relapsed or refractory multiple myeloma: effectiveness, value, and value-based price benchmarks. Final evidence report and meeting summary; 2016. Available from: https:\/\/icer-review.org\/announcements\/mm-final-report\/. Accessed October 07, 2020."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.clinthera.2019.01.009","volume":"41","author":"Ailawadhi","year":"2019","journal-title":"Clin Ther"},{"key":"ref31","unstructured":"IBM Micromedex.\u00a0 RED BOOK\u00ae 2019; 2019. Available from: https:\/\/www.ibm.com\/products\/micromedex-red-book. Accessed October 07, 2020."},{"key":"ref32","unstructured":"InHealth. Physicians\u2019 fee & coding guide 2019. Commercial fee range - fees on disc 2019. 2019."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3111\/13696998.2012.760159","volume":"16","author":"Durie","year":"2013","journal-title":"J Med Econ"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/annonc\/mdp535","volume":"21","author":"Foley","year":"2010","journal-title":"Ann Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J Med Econ"},{"key":"ref36","unstructured":"HCUPnet. Weighted national estimates from HCUP National Inpatient Sample (NIS), 2016, Agency for Healthcare Research and Quality (AHRQ), based on data collected by individual States and provided to AHRQ by the States. Statistics by Principal Diagnosis and Payer (insurance status); 2016. Available from: https:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp. Accessed October 07, 2020."}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=73540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=73540","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T09:00:34Z","timestamp":1631264434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/budget-impact-of-belantamab-mafodotin-belamaf-adoption-in-the-treatmen-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":37,"URL":"https:\/\/doi.org\/10.2147\/ceor.s310619","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}